Skip to main content
Signal8

Passage BIO, Inc. (PASG) Form 8-K — Nov 18, 2026

$PASGForm 8-KItems 3.01Filed Nov 18, 2026, 4:15 PM ET0001140361-26-044734Original filing

Passage Bio received a Nasdaq deficiency letter on November 12, 2026 for failing Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders' equity. The company reported just $50,000 in stockholders' equity in its Q3 2026 10-Q and did not meet alternative compliance standards. The deficiency has no immediate effect on listing. Passage Bio expects to cure it by completing its previously announced mergers with Remix Therapeutics, after which the combined company will rename to Remix Therapeutics and trade as RMTX.

Key figures

Reported stockholders equity
50000
Minimum stockholders equity requirement
2500000

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.